nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—Sirolimus—FGF2—cleft lip	0.036	1	CrCbGaD
Pimecrolimus—MTOR—PI-3K cascade—FGFR1—cleft lip	0.00232	0.0024	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—FGF10—cleft lip	0.00232	0.0024	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—FGF3—cleft lip	0.00231	0.00239	CbGpPWpGaD
Pimecrolimus—MTOR—IGF1R signaling cascade—FGFR3—cleft lip	0.0023	0.00239	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—FGFR3—cleft lip	0.0023	0.00239	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—FGF3—cleft lip	0.0023	0.00238	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FGF9—cleft lip	0.00229	0.00237	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—FGF9—cleft lip	0.00229	0.00237	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—FGF9—cleft lip	0.00229	0.00237	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—FGF9—cleft lip	0.00227	0.00235	CbGpPWpGaD
Pimecrolimus—MTOR—PI3K Cascade—FGF2—cleft lip	0.00227	0.00235	CbGpPWpGaD
Pimecrolimus—MTOR—PI3K/AKT activation—FGFR1—cleft lip	0.00226	0.00235	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—FGF9—cleft lip	0.00225	0.00233	CbGpPWpGaD
Pimecrolimus—MTOR—GAB1 signalosome—FGFR1—cleft lip	0.00224	0.00233	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—FGF9—cleft lip	0.00224	0.00232	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—FGF10—cleft lip	0.00222	0.0023	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—WNT9B—cleft lip	0.00221	0.00229	CbGpPWpGaD
Pimecrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—FGFR1—cleft lip	0.00219	0.00227	CbGpPWpGaD
Pimecrolimus—MTOR—PI-3K cascade—FGFR3—cleft lip	0.00219	0.00227	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—FGF10—cleft lip	0.00218	0.00226	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—FGF3—cleft lip	0.00217	0.00225	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—FGFR2—cleft lip	0.00217	0.00225	CbGpPWpGaD
Pimecrolimus—MTOR—LKB1 signaling events—MYC—cleft lip	0.00214	0.00222	CbGpPWpGaD
Pimecrolimus—MTOR—PI3K/AKT activation—FGFR3—cleft lip	0.00214	0.00222	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—FGF7—cleft lip	0.00213	0.00221	CbGpPWpGaD
Pimecrolimus—MTOR—GAB1 signalosome—FGFR3—cleft lip	0.00212	0.0022	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—FGF9—cleft lip	0.00212	0.0022	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—FGF10—cleft lip	0.00208	0.00216	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FGF3—cleft lip	0.00208	0.00216	CbGpPWpGaD
Pimecrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—FGFR3—cleft lip	0.00207	0.00215	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—FGF10—cleft lip	0.00207	0.00215	CbGpPWpGaD
Pimecrolimus—MTOR—Leptin signaling pathway—NOS3—cleft lip	0.00207	0.00214	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—FGF10—cleft lip	0.00206	0.00214	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—FGF10—cleft lip	0.00205	0.00213	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FGF9—cleft lip	0.00203	0.0021	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—FGFR1—cleft lip	0.00202	0.0021	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—FGF10—cleft lip	0.00202	0.0021	CbGpPWpGaD
Pimecrolimus—MTOR—TSLP Signaling Pathway—MYC—cleft lip	0.00199	0.00207	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—ABCA4—cleft lip	0.00197	0.00204	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—FGF8—cleft lip	0.00196	0.00204	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—FGF10—cleft lip	0.00193	0.002	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—FGF10—cleft lip	0.00193	0.002	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FGF10—cleft lip	0.00193	0.002	CbGpPWpGaD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—FGF2—cleft lip	0.00191	0.00199	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—FGFR3—cleft lip	0.00191	0.00199	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—FGF10—cleft lip	0.00191	0.00198	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-mediated signalling—FGF2—cleft lip	0.0019	0.00197	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—FGF10—cleft lip	0.0019	0.00197	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—FGF10—cleft lip	0.00189	0.00196	CbGpPWpGaD
Pimecrolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—FGF2—cleft lip	0.00188	0.00195	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—FGFR2—cleft lip	0.00186	0.00193	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events—FGF2—cleft lip	0.00184	0.00191	CbGpPWpGaD
Pimecrolimus—MTOR—Wnt Signaling Pathway Netpath—MYC—cleft lip	0.00184	0.00191	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—FGF2—cleft lip	0.00183	0.0019	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—SLC19A1—cleft lip	0.0018	0.00187	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—FGF10—cleft lip	0.00179	0.00185	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB Signaling Pathway—MYC—cleft lip	0.00178	0.00185	CbGpPWpGaD
Pimecrolimus—MTOR—IGF1R signaling cascade—FGF2—cleft lip	0.00178	0.00185	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—FGF2—cleft lip	0.00178	0.00185	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—FGFR2—cleft lip	0.00178	0.00184	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—FGF2—cleft lip	0.00176	0.00183	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—WNT3—cleft lip	0.00176	0.00182	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—FGFR2—cleft lip	0.00175	0.00182	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—FGFR1—cleft lip	0.00173	0.0018	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FGF10—cleft lip	0.00171	0.00177	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—MYC—cleft lip	0.0017	0.00176	CbGpPWpGaD
Pimecrolimus—MTOR—PI-3K cascade—FGF2—cleft lip	0.00169	0.00176	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—FGFR2—cleft lip	0.00167	0.00173	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—FGFR2—cleft lip	0.00166	0.00173	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—FGFR1—cleft lip	0.00166	0.00172	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—FGFR2—cleft lip	0.00165	0.00172	CbGpPWpGaD
Pimecrolimus—MTOR—PI3K/AKT activation—FGF2—cleft lip	0.00165	0.00171	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—FGFR2—cleft lip	0.00165	0.00171	CbGpPWpGaD
Pimecrolimus—MTOR—GAB1 signalosome—FGF2—cleft lip	0.00164	0.0017	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—FGFR3—cleft lip	0.00164	0.0017	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—FGFR1—cleft lip	0.00163	0.00169	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—FGFR2—cleft lip	0.00162	0.00168	CbGpPWpGaD
Pimecrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—FGF2—cleft lip	0.0016	0.00166	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—FGF3—cleft lip	0.0016	0.00166	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ARHGAP29—cleft lip	0.00159	0.00165	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—FGFR3—cleft lip	0.00157	0.00162	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—FGF9—cleft lip	0.00156	0.00162	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—FGFR1—cleft lip	0.00156	0.00162	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—NOS3—cleft lip	0.00156	0.00161	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—FGFR1—cleft lip	0.00155	0.00161	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—FGFR2—cleft lip	0.00155	0.00161	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FGFR2—cleft lip	0.00155	0.00161	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—FGFR2—cleft lip	0.00155	0.00161	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—WNT9B—cleft lip	0.00155	0.00161	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—FGFR1—cleft lip	0.00154	0.0016	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—FGFR3—cleft lip	0.00154	0.0016	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—FGFR2—cleft lip	0.00154	0.00159	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—FGFR1—cleft lip	0.00153	0.00159	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—FGFR2—cleft lip	0.00152	0.00158	CbGpPWpGaD
Pimecrolimus—MTOR—TSH signaling pathway—MYC—cleft lip	0.00152	0.00157	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—FGFR2—cleft lip	0.00152	0.00157	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—FGFR1—cleft lip	0.00151	0.00157	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—TCN2—cleft lip	0.00149	0.00155	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NOG—cleft lip	0.00148	0.00154	CbGpPWpGaD
Pimecrolimus—MTOR—Regulation of Telomerase—MYC—cleft lip	0.00148	0.00154	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—FGF2—cleft lip	0.00148	0.00153	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—FGFR3—cleft lip	0.00147	0.00153	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—NOS3—cleft lip	0.00147	0.00152	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—FGFR3—cleft lip	0.00146	0.00152	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—FGFR3—cleft lip	0.00146	0.00151	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—FGFR3—cleft lip	0.00145	0.0015	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—FGFR1—cleft lip	0.00144	0.0015	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—FGFR1—cleft lip	0.00144	0.0015	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FGFR1—cleft lip	0.00144	0.0015	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—FGFR2—cleft lip	0.00143	0.00149	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—FGFR1—cleft lip	0.00143	0.00148	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—cleft lip	0.00143	0.00148	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—FGFR1—cleft lip	0.00142	0.00147	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—FGFR1—cleft lip	0.00141	0.00146	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ABCA4—cleft lip	0.00138	0.00143	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FGFR2—cleft lip	0.00137	0.00142	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FGFR3—cleft lip	0.00136	0.00142	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—FGFR3—cleft lip	0.00136	0.00142	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—FGFR3—cleft lip	0.00136	0.00142	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—FGFR3—cleft lip	0.00135	0.0014	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—FGFR3—cleft lip	0.00134	0.00139	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—FGFR1—cleft lip	0.00134	0.00139	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—FGFR3—cleft lip	0.00133	0.00138	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—FGF10—cleft lip	0.00132	0.00136	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FGFR1—cleft lip	0.00128	0.00133	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—FGF2—cleft lip	0.00127	0.00131	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—FGFR3—cleft lip	0.00126	0.00131	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—WNT9B—cleft lip	0.00124	0.00129	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—WNT3—cleft lip	0.00123	0.00128	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—FGF7—cleft lip	0.00121	0.00126	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—FGF2—cleft lip	0.00121	0.00126	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FGFR3—cleft lip	0.00121	0.00125	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—FGF2—cleft lip	0.00119	0.00124	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—FGF7—cleft lip	0.00117	0.00121	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—SPRY2—cleft lip	0.00116	0.0012	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—FGF7—cleft lip	0.00116	0.0012	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—MYC—cleft lip	0.00115	0.0012	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—FGF2—cleft lip	0.00114	0.00118	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—FGF2—cleft lip	0.00113	0.00117	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IRF6—cleft lip	0.00113	0.00117	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—FGF2—cleft lip	0.00113	0.00117	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—FGF2—cleft lip	0.00112	0.00116	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—FGF8—cleft lip	0.00112	0.00116	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—NOS3—cleft lip	0.00112	0.00116	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—ABCA4—cleft lip	0.00111	0.00115	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—FGF2—cleft lip	0.0011	0.00115	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—FGF8—cleft lip	0.00108	0.00112	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—FGF8—cleft lip	0.00107	0.00111	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—FGFR2—cleft lip	0.00106	0.00109	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—FGF2—cleft lip	0.00105	0.00109	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FGF2—cleft lip	0.00105	0.00109	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—FGF2—cleft lip	0.00105	0.00109	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—FGF2—cleft lip	0.00105	0.00108	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—FGF2—cleft lip	0.00104	0.00107	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MTR—cleft lip	0.00103	0.00107	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—FGF2—cleft lip	0.00103	0.00107	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SLC19A1—cleft lip	0.00101	0.00105	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—WNT3—cleft lip	0.000987	0.00102	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—FGFR1—cleft lip	0.000984	0.00102	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—FGF2—cleft lip	0.000976	0.00101	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FGF2—cleft lip	0.000934	0.000969	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—FGFR3—cleft lip	0.00093	0.000964	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—FGF3—cleft lip	0.000912	0.000946	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—FGF9—cleft lip	0.000889	0.000923	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—FGF3—cleft lip	0.000876	0.000909	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—FGF3—cleft lip	0.000872	0.000905	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—WNT9B—cleft lip	0.00087	0.000903	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—FGF9—cleft lip	0.000854	0.000886	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—FGF9—cleft lip	0.00085	0.000882	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TCN2—cleft lip	0.00084	0.000871	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NOG—cleft lip	0.000834	0.000866	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FGF7—cleft lip	0.000813	0.000843	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SPRY2—cleft lip	0.000813	0.000843	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—MYC—cleft lip	0.000783	0.000812	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ABCA4—cleft lip	0.000776	0.000805	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—SUMO1—cleft lip	0.000773	0.000802	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—MTR—cleft lip	0.000756	0.000784	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FGF8—cleft lip	0.00075	0.000778	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—FGF10—cleft lip	0.00075	0.000778	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—FGF10—cleft lip	0.00072	0.000747	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—FGF2—cleft lip	0.000718	0.000745	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—FGF10—cleft lip	0.000717	0.000744	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—FGF7—cleft lip	0.000707	0.000734	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—WNT3—cleft lip	0.000691	0.000717	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PTCH1—cleft lip	0.000674	0.000699	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SPRY2—cleft lip	0.000653	0.000677	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—FGF7—cleft lip	0.000653	0.000677	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—FGF8—cleft lip	0.000653	0.000677	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FGF3—cleft lip	0.000611	0.000634	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—FGF8—cleft lip	0.000603	0.000625	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—FGFR2—cleft lip	0.000602	0.000624	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FGF9—cleft lip	0.000595	0.000618	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MTR—cleft lip	0.000582	0.000604	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—FGFR2—cleft lip	0.000578	0.0006	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—FGFR2—cleft lip	0.000576	0.000597	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—FGFR1—cleft lip	0.000561	0.000582	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MTHFR—cleft lip	0.000554	0.000575	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—FGFR1—cleft lip	0.000539	0.000559	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—FGFR1—cleft lip	0.000536	0.000557	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—FGF3—cleft lip	0.000531	0.000551	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—FGFR3—cleft lip	0.00053	0.00055	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—FGF9—cleft lip	0.000518	0.000537	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—FGFR3—cleft lip	0.000509	0.000528	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—FGFR3—cleft lip	0.000507	0.000526	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FGF10—cleft lip	0.000502	0.000521	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—FGF3—cleft lip	0.00049	0.000509	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—FGF9—cleft lip	0.000478	0.000496	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SPRY2—cleft lip	0.000457	0.000474	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FGF7—cleft lip	0.000457	0.000474	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—FGF10—cleft lip	0.000437	0.000453	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FGF8—cleft lip	0.000422	0.000438	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—FGF2—cleft lip	0.00041	0.000425	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—FGF10—cleft lip	0.000403	0.000418	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FGFR2—cleft lip	0.000403	0.000418	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—FGF2—cleft lip	0.000394	0.000408	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—FGF2—cleft lip	0.000392	0.000406	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—NOS3—cleft lip	0.000386	0.000401	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTCH1—cleft lip	0.000379	0.000393	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FGFR1—cleft lip	0.000376	0.00039	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FGFR3—cleft lip	0.000355	0.000368	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—FGFR2—cleft lip	0.000351	0.000364	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FGF3—cleft lip	0.000343	0.000356	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FGF9—cleft lip	0.000335	0.000347	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—FGFR1—cleft lip	0.000327	0.000339	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—FGFR2—cleft lip	0.000324	0.000336	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MTHFR—cleft lip	0.000312	0.000323	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—FGFR3—cleft lip	0.000309	0.00032	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—FGFR1—cleft lip	0.000302	0.000313	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—FGFR3—cleft lip	0.000285	0.000296	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FGF10—cleft lip	0.000282	0.000293	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FGF2—cleft lip	0.000274	0.000285	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NOS3—cleft lip	0.000271	0.000281	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MYC—cleft lip	0.000256	0.000266	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—FGF2—cleft lip	0.000239	0.000248	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FGFR2—cleft lip	0.000227	0.000235	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC19A1—cleft lip	0.000225	0.000233	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—FGF2—cleft lip	0.00022	0.000229	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NOS3—cleft lip	0.000217	0.000225	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FGFR1—cleft lip	0.000211	0.000219	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FGFR3—cleft lip	0.0002	0.000207	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—TCN2—cleft lip	0.000186	0.000193	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MYC—cleft lip	0.000179	0.000186	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FGF2—cleft lip	0.000154	0.00016	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NOS3—cleft lip	0.000152	0.000158	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MYC—cleft lip	0.000144	0.000149	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—MTR—cleft lip	0.000129	0.000134	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MYC—cleft lip	0.000101	0.000105	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—TYMS—cleft lip	7.92e-05	8.22e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—MTHFR—cleft lip	6.92e-05	7.18e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NOS3—cleft lip	4.83e-05	5.01e-05	CbGpPWpGaD
